Pushing the boundaries of medical research, French biopharmaceutical company Pharnext specialises in the development of drugs that help treat neurodegenerative diseases. The firm was formed by a group of renowned scientists led by Professor Daniel Cohen, a widely recognised pioneer in modern genomics.
Pharnext has received the green light for a Phase 3 international trial of a product for the treatment of Charcot-Marie-Tooth Type 1A, a designated orphan disease in the United States and Europe for which drugs may gain final approval via a much abbreviated procedure. The company has already obtained positive results for the Phase 2 trial of its PXT864 drug for the treatment of Alzheimer’s Disease.
Pharnext is a global leader in the development of PLEODRUG© which simultaneously target multiple disease pathways. The company has identified a number of synergic combinations of already existing drugs, effectively repurposing their use. This offers key advantages to patients and investors alike: PLEODRUG© are deemed effective, safe, and – crucially – enjoy protection under international intellectual property law.
In June 2016, Pharnext successfully debuted on the Paris Euronext Alternext stock exchange raising in excess of €30 million from mostly Tier-1 institutional investors. The initial public offering was significantly oversubscribed. The proceeds of the IPO will be invested in Pharnext’s already formidable research effort and provide liquidity for future undertakings.
The CFI.co judging panel congratulates the company on its flawlessly executed IPO and wishes to recognise this accomplishment by offering Pharnext the 2016 Best Life-Sciences IPO France Award.
SegurCaixa Adeslas, a pre-eminent Spanish health insurance company, has demonstrated a formidable and truly impressive…
Banco BPI's dedication to sustainability is a beacon of proactive environmental and social responsibility. Beyond…
BSE Ltd, formerly known as the Bombay Stock Exchange, is a crucial player in India’s…
TMT Investments Plc, publicly quoted on the AIM market of the London Stock Exchange since…
BNP Paribas Fortis is a key player in the Belgian banking sector with a rich…
BAWAG Group has reported 2023 net profit of 683 million euros, a ROTCE of 25…